Next Article in Journal
The OsCYP19-4 Gene Is Expressed as Multiple Alternatively Spliced Transcripts Encoding Isoforms with Distinct Cellular Localizations and PPIase Activities under Cold Stress
Next Article in Special Issue
Advanced Glycation End-Products Enhance Lung Cancer Cell Invasion and Migration
Previous Article in Journal
Progress in AQP Research and New Developments in Therapeutic Approaches to Ischemic and Hemorrhagic Stroke
Previous Article in Special Issue
MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer
Review

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints

by 1,2,3,†, 2,3,4,†, 1,2,3,4,5, 1,2,3,6, 1,2,3, 1,2,3,4,* and 1,2,3,4,*
1
Institute of Precision Medicine and Innovative Drug Discovery, Institute of Science and Technology, Hong Kong Baptist University, Haimen 226133, China
2
Institute of Integrated Bioinformedicine and Translational Science, Hong Kong Baptist University, Hong Kong, China
3
Institute of Research and Continuing Education, Hong Kong Baptist University, Hong Kong, China
4
Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
5
Faculty of Materials Science and Chemical Engineering, The State Key Laboratory Base of Novel Functional Materials and Preparation Science, Ningbo University, Ningbo 315211, China
6
College of Medicine, Jiaxing University, Jiaxing 314001, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work
Academic Editor: William Chi-shing Cho
Int. J. Mol. Sci. 2016, 17(7), 1151; https://doi.org/10.3390/ijms17071151
Received: 16 May 2016 / Revised: 27 June 2016 / Accepted: 7 July 2016 / Published: 18 July 2016
(This article belongs to the Collection Advances in Molecular Oncology)
Interference of the binding of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers. To date, the FDA has approved two PD-1 monoclonal antibody drugs against cancer as well as a monoclonal antibody for PD-L1. More PD-1 and PD-L1 monoclonal antibody drugs are on their way in clinical trials. In this review, we focused on the mechanism of the PD-1/PD-L1 signaling pathway and the monoclonal antibodies (mAbs) against PD-1 and PD-L1, which were approved by the FDA or are still in clinical trials. And also presented is the prospect of the PD-1/PD-L1 immune checkpoint blockade in the next generation of immunotherapy. View Full-Text
Keywords: Immunotherapy; PD-1 (Programmed cell death protein 1); PD-L1 (Programmed death-ligand 1); monoclonal antibodies (mAbs) Immunotherapy; PD-1 (Programmed cell death protein 1); PD-L1 (Programmed death-ligand 1); monoclonal antibodies (mAbs)
Show Figures

Figure 1

MDPI and ACS Style

Li, Y.; Li, F.; Jiang, F.; Lv, X.; Zhang, R.; Lu, A.; Zhang, G. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. Int. J. Mol. Sci. 2016, 17, 1151. https://doi.org/10.3390/ijms17071151

AMA Style

Li Y, Li F, Jiang F, Lv X, Zhang R, Lu A, Zhang G. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. International Journal of Molecular Sciences. 2016; 17(7):1151. https://doi.org/10.3390/ijms17071151

Chicago/Turabian Style

Li, Yongshu, Fangfei Li, Feng Jiang, Xiaoqing Lv, Rongjiang Zhang, Aiping Lu, and Ge Zhang. 2016. "A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints" International Journal of Molecular Sciences 17, no. 7: 1151. https://doi.org/10.3390/ijms17071151

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop